Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Warren Capell

Concepts (164)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Rivaroxaban
12
2022
211
2.200
Why?
Peripheral Arterial Disease
12
2022
380
1.750
Why?
Factor Xa Inhibitors
6
2021
138
1.230
Why?
Lower Extremity
9
2022
335
1.190
Why?
Aspirin
10
2022
324
1.190
Why?
Endovascular Procedures
5
2022
269
0.930
Why?
Thrombosis
2
2022
298
0.740
Why?
Beneficence
1
2021
18
0.730
Why?
Hypertriglyceridemia
3
2006
34
0.720
Why?
Research Subjects
1
2021
40
0.710
Why?
Personal Autonomy
1
2021
39
0.710
Why?
Informed Consent
2
2021
161
0.710
Why?
Patient Selection
2
2021
641
0.660
Why?
Ischemia
5
2022
362
0.630
Why?
Outpatients
1
2021
326
0.590
Why?
Platelet Aggregation Inhibitors
8
2022
401
0.580
Why?
Venous Thromboembolism
3
2023
231
0.470
Why?
Hospitalization
2
2021
1752
0.420
Why?
Lipoproteins
4
2010
159
0.400
Why?
Lipoprotein Lipase
2
2010
54
0.400
Why?
Risk Assessment
1
2021
2968
0.390
Why?
Double-Blind Method
6
2021
1660
0.360
Why?
Hypolipidemic Agents
3
2006
86
0.360
Why?
Fat Emulsions, Intravenous
1
2010
27
0.350
Why?
Hemorrhage
5
2023
620
0.280
Why?
Triglycerides
3
2010
467
0.270
Why?
Drug Therapy, Combination
5
2021
951
0.270
Why?
Glucose
1
2010
897
0.250
Why?
Myocardial Infarction
2
2022
927
0.240
Why?
Muscle, Skeletal
2
2010
1473
0.210
Why?
Fatty Acids, Nonesterified
3
2010
151
0.210
Why?
Male
19
2023
55669
0.210
Why?
Fenofibrate
1
2003
24
0.210
Why?
Fibrin Fibrinogen Degradation Products
1
2023
80
0.210
Why?
Antifibrinolytic Agents
1
2023
50
0.200
Why?
Middle Aged
13
2023
26740
0.200
Why?
Multicenter Studies as Topic
2
2021
249
0.200
Why?
Drug-Eluting Stents
1
2021
62
0.190
Why?
Clinical Trials, Phase III as Topic
1
2021
82
0.180
Why?
Pragmatic Clinical Trials as Topic
1
2021
47
0.180
Why?
Female
17
2023
59573
0.180
Why?
Humans
27
2023
114711
0.180
Why?
Blood Coagulation Disorders
1
2023
197
0.180
Why?
Follow-Up Studies
2
2021
4411
0.180
Why?
Clinical Trials as Topic
3
2021
932
0.180
Why?
Paclitaxel
1
2021
190
0.180
Why?
Placebos
1
2021
197
0.180
Why?
Extremities
1
2021
113
0.170
Why?
Vasodilation
1
2003
419
0.170
Why?
Cause of Death
1
2021
361
0.160
Why?
Vascular Surgical Procedures
1
2021
259
0.150
Why?
Subacute Care
1
2019
71
0.150
Why?
Treatment Outcome
6
2022
9089
0.150
Why?
Brain Ischemia
1
2021
299
0.150
Why?
Nursing Homes
1
2019
138
0.150
Why?
Dose-Response Relationship, Drug
2
2021
1842
0.140
Why?
Purinergic P2Y Receptor Antagonists
1
2018
62
0.140
Why?
Hospital Mortality
1
2021
776
0.140
Why?
Health Services Research
1
2019
371
0.130
Why?
Lipoproteins, LDL
1
1996
128
0.130
Why?
Randomized Controlled Trials as Topic
1
2021
1214
0.130
Why?
Skilled Nursing Facilities
1
2017
121
0.120
Why?
Insulin Resistance
3
2013
1072
0.120
Why?
Consensus
1
2017
539
0.120
Why?
Fibrinolytic Agents
1
2017
234
0.120
Why?
Ethics, Research
1
2014
34
0.110
Why?
Anticoagulants
3
2023
550
0.110
Why?
Societies, Medical
1
2017
664
0.110
Why?
Disease Management
1
2017
560
0.110
Why?
Cardiovascular Diseases
2
2021
1728
0.110
Why?
Stroke
1
2021
1022
0.110
Why?
Caspase 1
1
2013
140
0.100
Why?
Aged
8
2022
19075
0.100
Why?
Interleukin-18
1
2013
219
0.100
Why?
Heparin
2
2023
224
0.090
Why?
Research Design
1
2017
928
0.090
Why?
Postoperative Complications
1
2021
2128
0.090
Why?
Biomedical Research
1
2017
585
0.090
Why?
Interleukin-1beta
1
2013
370
0.090
Why?
Arteries
2
2022
247
0.090
Why?
Transfection
2
2010
866
0.090
Why?
Dietary Fats
2
2010
287
0.090
Why?
Lactones
1
2010
54
0.080
Why?
Diet, Carbohydrate-Restricted
1
2010
28
0.080
Why?
Myoblasts
1
2010
76
0.080
Why?
Diet, Fat-Restricted
2
2010
73
0.080
Why?
Obesity
2
2013
2508
0.080
Why?
Hypercholesterolemia
1
2010
90
0.080
Why?
Inflammation
2
2023
2480
0.080
Why?
Kaplan-Meier Estimate
2
2021
811
0.080
Why?
Palliative Care
1
2014
644
0.070
Why?
Blotting, Western
1
2010
1147
0.070
Why?
Adult
5
2021
30562
0.070
Why?
Simvastatin
1
2006
59
0.070
Why?
Temperance
1
2005
13
0.060
Why?
Cross-Over Studies
2
2006
440
0.060
Why?
Weight Loss
1
2010
642
0.060
Why?
Anticholesteremic Agents
1
2006
128
0.060
Why?
Cell Line
1
2010
2637
0.060
Why?
Treatment Failure
1
2005
330
0.060
Why?
C-Reactive Protein
1
2006
362
0.060
Why?
Incidence
2
2021
2314
0.060
Why?
Heart Failure
1
2017
1945
0.060
Why?
Thromboplastin
1
2023
71
0.050
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2006
373
0.050
Why?
Forearm
1
2003
112
0.050
Why?
Vesicular Transport Proteins
1
2003
83
0.050
Why?
Metabolic Syndrome
1
2005
321
0.050
Why?
Numbers Needed To Treat
1
2021
8
0.050
Why?
Fasting
1
2003
241
0.050
Why?
Regional Blood Flow
1
2003
424
0.050
Why?
Postmenopause
1
2003
303
0.050
Why?
Antineoplastic Agents, Phytogenic
1
2021
181
0.040
Why?
Muscle, Smooth, Vascular
1
2003
411
0.040
Why?
Lipid Metabolism
1
2003
444
0.040
Why?
Internationality
1
2020
143
0.040
Why?
Alcohol Drinking
1
2005
652
0.040
Why?
Mice
3
2013
14872
0.040
Why?
Nerve Tissue Proteins
1
2003
530
0.040
Why?
Algorithms
1
2006
1470
0.040
Why?
Confidentiality
1
2019
67
0.040
Why?
Global Health
1
2021
287
0.040
Why?
Acute Disease
1
2021
911
0.040
Why?
Practice Guidelines as Topic
1
2006
1394
0.040
Why?
Proportional Hazards Models
1
2021
1075
0.040
Why?
Proteins
1
2003
908
0.040
Why?
Membrane Proteins
1
2003
1019
0.030
Why?
Combined Modality Therapy
1
2020
1121
0.030
Why?
Cholesterol, LDL
2
2010
307
0.030
Why?
Risk Factors
2
2022
8634
0.030
Why?
Arteriosclerosis
1
1996
83
0.030
Why?
Patient Safety
1
2019
277
0.030
Why?
Particle Size
1
1996
317
0.030
Why?
Patient Transfer
1
2017
143
0.030
Why?
Reference Values
1
1996
743
0.030
Why?
Animals
3
2013
31710
0.030
Why?
Disease Susceptibility
1
1996
316
0.030
Why?
Ethics Committees, Research
1
2014
38
0.030
Why?
Diabetes Mellitus, Type 2
1
2006
2093
0.030
Why?
Research Personnel
1
2014
149
0.030
Why?
Cohort Studies
1
2022
4895
0.030
Why?
Diet, High-Fat
1
2013
225
0.020
Why?
Prospective Studies
1
2022
6220
0.020
Why?
Diet, Reducing
1
2010
76
0.020
Why?
Quality Improvement
1
2017
950
0.020
Why?
Dietary Carbohydrates
1
2010
138
0.020
Why?
Body Weight
1
2013
869
0.020
Why?
Phenotype
1
1996
2797
0.020
Why?
Communication
1
2014
744
0.020
Why?
Sex Factors
1
2013
1715
0.020
Why?
Energy Intake
1
2010
427
0.020
Why?
Mice, Knockout
1
2013
2570
0.020
Why?
Retrospective Studies
1
2003
12558
0.020
Why?
Dyslipidemias
1
2006
154
0.020
Why?
Munc18 Proteins
1
2003
23
0.010
Why?
SNARE Proteins
1
2003
37
0.010
Why?
Time Factors
1
2013
6114
0.010
Why?
Muscle Fibers, Skeletal
1
2003
185
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2003
740
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2003
923
0.010
Why?
Insulin
1
2010
2082
0.010
Why?
Mice, Transgenic
1
2003
1950
0.010
Why?
Cells, Cultured
1
2003
3886
0.010
Why?
Blood Glucose
1
2003
1828
0.010
Why?
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)